News | June 01, 2023
Laurus Labs to increase stake in ImmunoACT to 33.86%
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Transformation to pure-play Innovative Medicines company nears completion
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
Subscribe To Our Newsletter & Stay Updated
